Drug Profile
VB 1953
Alternative Names: VB-1953Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Vyome Biosciences
- Developer Vyome Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials
- Mechanism of Action Bacterial growth inhibitors; Carrier protein inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Toll-like receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acne
Most Recent Events
- 07 Dec 2022 VB 1953 is still in phase II trials for Acne in USA (NCT03900676) (Vyome Therapeutics pipeline, December 2022)
- 16 Jun 2020 Efficacy and adverse events data from a phase II trial in Acne released by Vyome Therapeutics
- 28 Feb 2020 No recent reports of development identified for clinical-Phase-Unknown development in Acne in Central America (Topical, Gel)